In conclusion, this study adds convincing support to the hypothesis that mosaic expression of hyperactive HRAS in bone, and not skin, leads to increased bioactive FGF23 secretion and, consequently, the FGF23-mediated hypophosphatemia and osteomalacia observed in CSHS. The gene discussed is FGF23; the disease is hypophosphatemia.